1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chiome Bioscience Inc.
  6. News
  7. Summary
    4583   JP3205350006

CHIOME BIOSCIENCE INC.

(4583)
  Report
Delayed Japan Exchange  -  02:00 2022-08-12 am EDT
166.00 JPY    0.00%
07/14Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma
MT
07/13Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience
MT
07/13CHIOME BIOSCIENCE : Announcement of target-specific research and option agreement with Heidelberg Pharma
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiome Bioscience : First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial

07/04/2022 | 02:23am EDT

July 4, 2022

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

First patient in of cancer therapeutic antibody CBA-1535

in a Phase 1 clinical trial

Chiome Bioscience Inc. announced today that the first patient has been dosed CBA-1535 in a Phase I clinical trial.

The first part of the trial will evaluate the safety, tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients. In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizumab. This first-in-human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center. We will continue to update the future process in a timely manner.

There is no impact on the financial performance in the fiscal period ending December 31, 2022.

About CBA-1535

CBA-1535 is cancer therapeutic antibody with three antigen binding sites; two of them are used for the binding with 5T4 protein that expresses multiple type of solid tumor, and one is for the binding with CD3 protein on the surface of immune T cells. CBA-1535 is anticipated to have strong cytotoxicity arisen from T cell proliferation and activation. CBA-1535 is targeted for refractory cancer such as malignant mesothelioma, small cell lung cancer, and non-small cell lung cancer and for solid tumor such as kidney, ovarian, and breast cancer.

Inquiries

Chiome Bioscience Inc. Investor Relations E-mail:ir@chiome.co.jp

Disclaimer

Chiome Bioscience Inc. published this content on 04 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 July 2022 06:22:06 UTC.


© Publicnow 2022
All news about CHIOME BIOSCIENCE INC.
07/14Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma
MT
07/13Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience
MT
07/13CHIOME BIOSCIENCE : Announcement of target-specific research and option agreement with Hei..
PU
07/13Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agre..
CI
07/12Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expa..
MT
07/11Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibod..
MT
07/11CHIOME BIOSCIENCE : Service agreement with option contract with Rohto Pharmaceutical Co., ..
PU
07/11Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Phar..
CI
07/04CHIOME BIOSCIENCE : First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 ..
PU
07/04Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-15..
CI
More news
Financials
Sales 2021 730 M 5,46 M 5,46 M
Net income 2021 -1 100 M -8,23 M -8,23 M
Net Debt 2021 - - -
P/E ratio 2021 -6,01x
Yield 2021 -
Capitalization 7 148 M 53,5 M 53,5 M
Capi. / Sales 2021 9,79x
Capi. / Sales 2022 9,53x
Nbr of Employees 53
Free-Float 93,8%
Chart CHIOME BIOSCIENCE INC.
Duration : Period :
Chiome Bioscience Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHIOME BIOSCIENCE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 166,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Shigeru Kobayashi Senior Director-Business Development
Akiyuki Furuya Independent Outside Director
Haruhisa Kubota Independent Outside Director
Arihiko Bijohira Manager-Corporate Planning
Sector and Competitors
1st jan.Capi. (M$)
CHIOME BIOSCIENCE INC.-14.87%53
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068